AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: ALLO
Report Date: 2026-04-13
Full Report: https://amaly.io/stock/ALLO

EXECUTIVE SUMMARY
------------------
Compliance Status: NON_COMPLIANT
Quality Rating: B
Description: Allogene Therapeutics, Inc. (ALLO) operates in an unknown industry with a focus on biotechnology R&D as inferred from available data. The company passes debt and income ratio screens but fails liquidity thresholds across all standards due to high cash holdings of 91.4% of market cap. Business activities appear permissible with no identified non-compliant revenue. However, exclusion from all major Shariah indices results in an overall non-compliant status. Investors should monitor cash deployment for potential future compliance.

Primary Compliance Concerns:
- Liquidity ratio of 91.4% exceeds 30-33% thresholds across AAOIFI, MSCI, and S&P standards

Purification Requirement: 1.63%
Index Inclusion: Not included in S&P Dow Jones Shariah Indices, MSCI Islamic Indices, FTSE Shariah Indices, or Dow Jones Islamic Market (DJIM)

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 26.5%
Liquidity Ratio: 91.4%
Interest Income Ratio: 1.6%
Purification Required: 1.63%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: EXCLUDED
MSCI Islamic: EXCLUDED
DJIM: EXCLUDED
FTSE Shariah: EXCLUDED
Total: 0 of 4
Last Verified: 2025-12-31

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2025
Latest Quarterly Data: Q4 2025
Trend Period: FY 2021 to FY 2025
Data Retrieved: 2026-02-20T12:00:00Z

---
Full interactive report: https://amaly.io/stock/ALLO
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.